Fosun Pharma subsidiary inks drug development, licensing deal with Clavis Bio

Fosun Pharmaceutical Industrial Development Co., Ltd., a controlled subsidiary of Shanghai Fosun Pharmaceutical Group, has signed a "Master Collaboration and Option Agreement" with Clavis Bio, Inc. The agreement, effective from December 18, 2025, for five years, establishes a partnership for the preclinical development of compounds targeting selected disease pathways. Clavis Bio will identify up to four targets annually, with development costs shared between the parties.

Under the agreement, Clavis Bio gains an exclusive option for global development, manufacturing, and commercialization rights outside of Mainland China, Hong Kong, and Macau. Fosun Pharma retains exclusive rights within these territories. If Clavis Bio exercises its option for a project, Fosun Pharma stands to receive up to $36,250,000 in non-refundable option fees, development, regulatory, and sales milestone payments, along with a percentage of net sales as royalties.

Additionally, Fosun Pharma will receive a minority equity stake in any new project company established by Aditum Bio Fund 3 (Clavis Bio’s controlling shareholder) for the specific collaboration project, at zero consideration. Aditum Bio Fund 3, a fund under Aditum Bio Management Company, LLC, has raised $428,000,000 as of December 18, 2025.